不再落后PD-1 有了新的免疫疗法伙伴

IF 25.5 1区医学 Q1 IMMUNOLOGY

Immunity Pub Date : 2024-10-08 DOI:10.1016/j.immuni.2024.09.010

Andrew J. Gunderson

引用次数: 0

摘要

PD-1阻断可部分逆转癌症患者的T细胞衰竭，但广泛的反应仍然有限。最近发表在《细胞》（Cell）杂志上的三项研究阐明了消减LAG-3和PD-1如何通过不同的分子机制协同进一步推动效应T细胞的功能。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

LAGging behind no more: PD-1 has a new immunotherapy partner

PD-1 blockade partially reverses T cell exhaustion in cancer patients, but broad responses are still limited. Three studies recently published in Cell illuminate how abrogating LAG-3 and PD-1 synergize to further push effector T cell functionality via distinct molecular mechanisms.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Immunity 医学-免疫学

CiteScore

49.40

自引率

2.20%

发文量

205

审稿时长

6 months

期刊介绍： Immunity is a publication that focuses on publishing significant advancements in research related to immunology. We encourage the submission of studies that offer groundbreaking immunological discoveries, whether at the molecular, cellular, or whole organism level. Topics of interest encompass a wide range, such as cancer, infectious diseases, neuroimmunology, autoimmune diseases, allergies, mucosal immunity, metabolic diseases, and homeostasis.